Adagene Inc

ADAG

Company Profile

  • Business description

    Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

  • Contact

    Xinghu Street, Suzhou Industrial Park
    4th Floor, Building C14, No. 218
    Jiangsu Province
    Suzhou215123
    CHN

    T: +86 51287773632

    https://www.adagene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    128

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,932.4064.90-0.72%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,165.78593.64-1.17%
FTSE 10010,551.17138.70-1.30%
HKSE23,294.75213.42-0.91%
NASDAQ24,407.6879.290.33%
Nikkei 22559,024.28163.850.28%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,319.4021.13-0.29%
S&P/ASX 2008,821.8061.40-0.69%
SSE Composite Index3,587.833.250.09%

Market Movers